The purpose of this study is to assess the long-term safety and to explore the efficacy of astegolimab in participants with chronic obstructive pulmonary disease (COPD) who have completed the 52-week placebo-controlled treatment period in parent studies GB43311 or GB44332.
Participants will receive SC astegolimab Q2W
La Plata, Buenos Aires, Argentina
Lobos, Buenos Aires, Argentina
Buenos Aires, Argentina
Buenos Aires, Argentina
Buenos Aires, Argentina
Buenos Aires, Argentina
Buenos Aires, Argentina
Buenos Aires, Argentina
CABA, Argentina
Ciudad Autonoma Buenos Aires, Argentina
Ciudad Autonoma Buenos Aires, Argentina
Ciudad Autonoma Buenos Aires, Argentina
Concepción del Uruguay, Argentina
Córdoba, Argentina
Córdoba, Argentina
Entre Ríos, Argentina
La Plata, Argentina
La Plata, Argentina
Mar del Plata, Argentina
Mar del Plata, Argentina
Mar del Plata, Argentina
Mendoza, Argentina
Mendoza, Argentina
Mendoza, Mendoza City, Argentina
Quilmes, Argentina
Ranelagh, Berazategui, Argentina
Rosario, Argentina
Rosario, Argentina
Rosario, Argentina
Rosario, Argentina
Rosario, Argentina
San Fernando, Argentina
San Miguel de Tucumán, Argentina
San Miguel de Tucumán, Argentina
San Miguel de Tucumán, Argentina
San Nicolás de los Arroyos, Argentina
San Salvador, Argentina
Santa Fe, Argentina
Santa Fe, Argentina
Villa Vatteone, Argentina
CONTACT